Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The closing price of Zymeworks BC Inc (NASDAQ: ZYME) was $26.52 for the day, up 1.14% from the previous closing price of $26.22. In other words, the price has increased by $1.14 from its previous closing price. On the day, 0.61 million shares were traded. ZYME stock price reached its highest trading level at $26.96 during the session, while it also had its lowest trading level at $25.91.
Ratios:
Our analysis of ZYME’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 6.94 and its Current Ratio is at 6.94. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In the most recent recommendation for this company, Citizens JMP on December 03, 2025, initiated with a Mkt Outperform rating and assigned the stock a target price of $32.
H.C. Wainwright Upgraded its Neutral to Buy on October 14, 2025, while the target price for the stock was maintained at $26.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 24 ’25 when Derek John Michael Miller bought 118,000 shares for $23.82 per share.
Neil Gallagher bought 105,000 shares of ZYME for $2,501,100 on Nov 21 ’25. On May 15 ’25, another insider, EcoR1 Capital, LLC, who serves as the Director of the company, bought 49,502 shares for $11.43 each. As a result, the insider paid 565,847 and bolstered with 17,877,989 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZYME now has a Market Capitalization of 2008502400 and an Enterprise Value of 1751635840. For the stock, the TTM Price-to-Sale (P/S) ratio is 14.87 while its Price-to-Book (P/B) ratio in mrq is 6.27. Its current Enterprise Value per Revenue stands at 13.025 whereas that against EBITDA is -28.728.
Stock Price History:
The Beta on a monthly basis for ZYME is 1.30, which has changed by 0.84000003 over the last 52 weeks, in comparison to a change of 0.12469888 over the same period for the S&P500. Over the past 52 weeks, ZYME has reached a high of $28.49, while it has fallen to a 52-week low of $9.03. The 50-Day Moving Average of the stock is 34.07%, while the 200-Day Moving Average is calculated to be 80.77%.
Shares Statistics:
ZYME traded an average of 1.12M shares per day over the past three months and 1491970 shares per day over the past ten days. A total of 75.14M shares are outstanding, with a floating share count of 72.92M. Insiders hold about 3.30% of the company’s shares, while institutions hold 99.50% stake in the company. Shares short for ZYME as of 1763078400 were 8541535 with a Short Ratio of 7.63, compared to 1760486400 on 7047624. Therefore, it implies a Short% of Shares Outstanding of 8541535 and a Short% of Float of 16.73.
Earnings Estimates
As of right now, 10.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$0.1, with high estimates of $0.55 and low estimates of -$0.41.
Analysts are recommending an EPS of between -$0.13 and -$1.25 for the fiscal current year, implying an average EPS of -$0.88. EPS for the following year is $0.25, with 11.0 analysts recommending between $3.76 and -$1.52.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 9 analysts. It ranges from a high estimate of $59M to a low estimate of $1.2M. As of. The current estimate, Zymeworks BC Inc’s year-ago sales were $31.03MFor the next quarter, 9 analysts are estimating revenue of $22.6M. There is a high estimate of $29.8M for the next quarter, whereas the lowest estimate is $14.58M.
A total of 11 analysts have provided revenue estimates for ZYME’s current fiscal year. The highest revenue estimate was $162.09M, while the lowest revenue estimate was $104.5M, resulting in an average revenue estimate of $124.33M. In the same quarter a year ago, actual revenue was $76.3MBased on 11 analysts’ estimates, the company’s revenue will be $246.12M in the next fiscal year. The high estimate is $502.1M and the low estimate is $96.08M.
